Abstract
Purpose
We have previously reported the expression of muscarinic acetylcholine receptors (mAChR) in human breast tumors. The activation of these receptors triggered tumor cell proliferation. Considering that invasion and metastasis is the major cause of death in cancer, we investigated the action of autoantibodies against mAChR derived from breast cancer patients in stage I (T1N0Mx-IgG) on MCF-7 cells migration and metalloproteinase-9 (MMP-9) activity. We also analyzed the participation of phospholipase C/nitric oxide synthase/protein kinase C pathway.
Methods
Immunoglobulin G (IgG) was purified by chromatography in protein G-agarose from blood samples of breast cancer patients obtained under informed consent. Migration was assayed by an in vitro wound assay. MMP-9 activity was quantified by zymography.
Results
T1N0Mx-IgG promoted tumor cell migration and increased MMP9 activity mimicking the action of the muscarinic agonist carbachol. This effect was reduced not only by the presence of atropine but also by 4-DAMP or tropicamide, antagonists for M3 and M4 mAChR subtypes respectively. The actions of T1N0Mx-IgG and carbachol on MCF-7 cells, involved the participation of phospholipase C/nitric oxide synthase/protein kinase C pathway.
Conclusions
IgG from breast cancer patients in stage I could be promoting tumor progression by regulating migration and MMP-9 activity in tumor cells via mAChR activation. The presence of these autoantibodies could be determining the prognosis of breast cancer in these patients.
Similar content being viewed by others
References
Jakóbisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett. 2003;90:103–22.
Hansen MH, Nielsen H, Ditzel HJ. The tumor infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA. 2001;98:12659–64.
Pagès F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leuk Biol. 2008;84:981–7.
Sogn JA. Tumor Immunology: the glass is half full. Immunity. 1998;9:757–63.
Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B. Tuning tumor-specific T cell activation: a matter of costimulation? Trends Immunol. 2002;23:240–5.
Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol Today. 1996;17:39–45.
Fiszman GL, Sales ME. Autoantibodies against muscarinic receptors in breast cancer. Agonizing tumor growth? Curr Immunol Rev. 2008;4:176–82.
Eglen RM. Muscarinic receptor subtype: pharmacology and physiology. Prog Med Chem. 2005;43:105–36.
Peraza-Cruces K, Gutiérrez-Guédez L, Castañeda Perozo D, Lankford CR, Rodríguez-Bonfante C, Bonfante-Cabarcas R. Trypanosoma cruzi infection induces up-regulation of cardiac muscarinic acetylcholine receptors in vivo and in vitro. Braz J Med Biol Res. 2008;41:796–803.
Koch HJ, Haas S, Jürgens T. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer’s disease. Curr Med Chem. 2005;12:2915–21.
Shah N, Khurana S, Cheng K, Raufman JP. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol. 2009;296:C221–32.
Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci. 2001;22:368–76.
Español AJ, de la Torre E, Fiszman GL, Sales ME. Role of non neuronal cholinergic system in breast cancer progression. Life Sci. 2007;80:2281–5.
Paleari L, Grozzio A, Cesario A, Russo P. The cholinergic system in cancer. Semin Cancer Biol. 2008;18:211–7.
Brábek J, Mierke CT, Rösel D, Veselý P, Fabry B. The sole of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal. 2010;8:1–8.
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
Negroni MP, Fiszman GL, Azar ME. Cresta Morgado C, Español AJ, Pelegrina LT, de la Torre E, Sales ME. Immunoglobulin G from breast cancer patients in stage I stimulates muscarinic acetylcholine receptors in MCF-7 cells and induces proliferation. Participation of nitric oxide synthase-derived nitric oxide. J Clin Immunol. 2010;30:474–84.
Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res. 1977;104:255–62.
Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
Wessler I, Kilbinger H, Bittinger F, Kirpatrik CJ. The non neuronal cholinergic system in humans: expression, function and pathophysiology. Life Sci. 2003;72:2055–61.
Wessler I, Kirpatrik CJ, Racke K. Non neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther. 1998;77:59–79.
Fiszman GL, Middonno MC, de la Torre E, Farina M, Español AJ, Sales ME. Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol Ther. 2007;6:1106–13.
Raufman JP, Samimi R, Shah N, Khurana S, Shant J, Drachenberg C, et al. Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res. 2008;68:3573–8.
Zhang S, Togo S, Minakata K, Gu T, Ohashi R, Tajima K, et al. Distinct roles of cholinergic receptors in small cell lung cancer cells. Anticancer Res. 2010;30:97–106.
Chernyavsky AI, Nguyen VT, Arredondo J, Ndoye A, Zia S, Wess J, et al. The M4 muscarinic receptor-selective effects on keratinocyte crawling locomotion. Life Sci. 2003;72:2069–73.
Desmetz C, Cortijo C, Mange A, Solassol J. Humoral response to cancer as a tool for biomarker discovery. J Proteome. 2009;72:982–8.
Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res. 2009;15:4733–41.
Fiszman G, Cattaneo V, de la Torre E, Español A, Colombo LL, de Lustig Sacerdote E, et al. Muscarinic receptors autoantibodies purified from mammary adenocarcinoma bearing mice sera stimulate tumor progression”. Int Immunopharmacol. 2006;6:1323–30.
Chiu CC, Chen BH, Hour TC, Chiang WF, Wu YJ, Chen CY, et al. Betel quid extract promotes oral cancer cell migration by activating a muscarinic M4 receptor-mediated signaling cascade involving SFKs and ERK1/2. Biochem Biophys Res Commun. 2010;399:60–5.
Rocha Duarte Cintra J, Bustamante Teixeira MT, Wolp Diniz R, Gonçalves Junior H, Marinho Florentino T, de Freitas Fialho G, et al. Immunohistochemical profile and clinical-pathological variables in breast cancer. Rev Assoc Med Bras. 2012;58:178–87.
Schulze W, Kunze R, Wallukat G. Pathophysiological role of autoantibodies against G-protein-coupled receptors in the cardiovascular system. Exp Clin Cardiol. 2005;10:170–2.
Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010;70:2224–34.
Houssami N, Cheung MN, Dixon JM. Fibroadenoma of the breast. Med J Aust. 2001;174:185–8.
You J, Mi D, Zhou X, Qiao L, Zhang H, Zhang X, et al. A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology. 2009;150:1607–17.
Sales ME. Tumor growth is stimulated by muscarinic receptors agonism. role of autoantibodies from breast cancer patients. Immunol Endocr Metabol Agents Med Chem. 2012; 3:208–15.
Acknowledgments
The authors want to thank Mrs. María Ester Castro for her excellent technical assistance. This work was supported by grants from the University of Buenos Aires (UBACYT M064) and from the National Agency for Scientific and Technology Promotion (ANPCyT) (PICT 2006-485). Drs. Gabriela Lombardi and María Elena Sales are established investigators at the National Research Council of Argentina (CONICET). Dr. Laura T. Pelegrina is a fellow from CONICET.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pelegrina, L.T., Lombardi, M.G., Fiszman, G.L. et al. Immunoglobulin G from Breast Cancer Patients Regulates MCF-7 Cells Migration and MMP-9 Activity by Stimulating Muscarinic Acetylcholine Receptors. J Clin Immunol 33, 427–435 (2013). https://doi.org/10.1007/s10875-012-9804-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-012-9804-y